Ajuts a la recerca

General Request for Proposals - The Alzheimer's Drug Discovery Foundation (ADDF)

Organisme

ALZHEIMER'S DRUG DISCOVERY FOUNDATION

Objecte

The Alzheimer's Drug Discovery Foundation supports promising, diverse international research projects to develop new drugs for Alzheimer's and related dementias, including vascular, Lewy body, and frontotemporal dementias.
ADDF's goal is to fill the critical translational funding gap that exists between basic research and later-stage drug development. ADDF funds three categories of research:

• Drug discovery and preclinical development, including high throughput screening, medicinal chemistry, lead optimization, in vivo efficacy, safety and toxicology, formulation of the drug, and scale-up
• Clinical trials
• Early detection, such as biomarkers and neuroimaging

Descripció

Característiques principals 
FUNDING MECHANISMS:

• Drug Discovery RFP: programs that aim to i) advance novel lead molecules to the clinical candidate selection stage (defined as compounds suitable for IND-enabling studies); or ii) build preclinical evidence in relevant animal models for repurposed/repositioned drugs or natural products.
• Program to Accelerate Clinical Trials (PACT) RFP: this program will fund (1) clinical trials through Phase 2a of novel drug candidates, including small molecules and biologics (antibodies, oligonucleotides, peptides, gene therapies, cell therapies); (2) proof-of-concept biomarker-based trials in patients for repurposed/repositioned drugs*; (3) regulatory studies for investigational new drug (IND)/clinical trial application (CTA) preclinical packages that are required before testing novel drugs in human subjects.
• Biomarkers Development RFP: this program seeks to support the development and validation of biomarkers that will enhance the design and performance of clinical trials for Alzheimer's disease and related dementias. This includes companion biomarkers for specific clinical-stage therapies and biomarkers with broader applicability across trials and therapeutic targets.
• Prevention Beyond the Pipeline RFP: this program seeks to support comparative effectiveness research, clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline.

DOTACIÓ

• Drug discovery: $150,000 - $600,000
• Program to accelerate clinical trials : up to $3 million
• Biomarkers development: $150,000 - $300,000
• Prevention beyond the pipeline: $50,000-$100,000 (epidemiological analyses), up to $3 million

DURADA

• Drug discovery: 1 year, potential for follow-up funding
• Program to accelerate clinical trials : multi-year
• Biomarkers development: 1-2 years, potential for follow-up funding
• Prevention beyond the pipeline: 1 year (epidemiological analyses), multi-year (clinical trials)

AVÍS IMPORTANT 
Deadlines for 2018 RFPs: 
LETTERS OF INTENT:

• January 19,
• April 13
• July 13
• October 12
  INVITED FULL PROPOSALS:
• February 9
• May 11
• August 10
• November 9

Pujar